Vimarsana
Biggest News Aggregation in the World

Patrick Barth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Barth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Barth Today - Breaking & Trending Today

Astrazeneca - Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy through 66 weeks - Vimarsana News

Astrazeneca - Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023

AstraZeneca password lapse exposed patient data - Vimarsana News

AstraZeneca password lapse exposed patient data

Internal passwords were online for more than a year before a good-faith security researcher found them.

New source for planetary water explored - Vimarsana News

New source for planetary water explored

Water is essential for life on Earth, but where does water on planets come from? Previously it had been suggested that water was delivered by comets

F. Hoffmann-La Roche Ltd: Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab) - Vimarsana News

F. Hoffmann-La Roche Ltd: Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab)

Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1The VENTANA PD-L1 (SP263) Assay helps determine which non-small

F. Hoffmann-La Roche Ltd: FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovascular or wet age-related macular degeneration (nAMD) - Vimarsana News

F. Hoffmann-La Roche Ltd: FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovascular or wet age-related macular degeneration (nAMD)

Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy